To provide the information your oncologist is not telling you or doesn't have the time to!
Explore a comprehensive range of insights and information within our ‘Varied Cancer Perspectives’ category. From melanoma to breast cancer, colorectal cancer to sarcoma, and beyond, this diverse collection delves into the multifaceted world of oncology. Gain a nuanced understanding of different cancer types, treatments, and the latest advancements in research. Whether you’re seeking knowledge on pediatric oncology, uveal melanoma, or desmoid tumors, our curated content provides a holistic view, offering valuable perspectives to empower and inform those navigating the complexities of cancer care. Join us on a journey through varied perspectives, ensuring a well-rounded understanding of the ever-evolving landscape of cancer.
Article written by one of our Melanoma/Sarcoma Clinical Trial Coordinators Chloe Caldwell to a target audience of healthcare providers regarding a new ongoing protocol for patients dealing with GIST open globally and at the Orlando Health Cancer Institute. All information posted here is publicly available here. Gastrointestinal Stromal Tumors (GIST) constitute a category of soft …
ASCO 2023 was an incredible conference and I had completely enjoyed the networking, presentations, and evening meetings. Here are two melanoma clinical trials that we had also participated in enrollment at the Orlando Health Cancer Institute. It is incredibly exciting to see patients do better with improved responses as well as improved odds of not …
ASCO 2023 was a ton of fun and lot of learning. In the coming weeks, I’ll share select abstracts that I thought were most important. This article discusses data from a groundbreaking PROSPECT trial which was presented as a Plenary topic at Chicago and published in NEJM last week. Ultimately, this creates more treatment options …
Replaying this post as a reminder that this study is enrolling at multiple sites globally. More detailed information can also be seen here at clinicaltrials.gov as well as the sponsor Iovance. All information and data stated in this article are available publicly through online resources that I’ve also linked below for reference. This new trial …
mRNA technology has revolutionized the world of medicine. Known for its role in the creation of COVID-19 vaccines, mRNA has been lauded as a game-changer in the fight against infectious diseases. But mRNA’s impact extends far beyond pandemic control. It’s now making waves in another critical area of healthcare: cancer treatment and prevention. mRNA stands …
I am really excited about this new protocol specifically for patients with MAGE4+ HLA restricted SPEAR TILs for Metastatic Melanoma, Non-small Cell Lung Cancer, Head Neck cancer, Ovarian, Endometrial, and Urothelial cancers. The Gastric and Esophageal Cancer cohorts are closed. The social media material seen here was approved both the sponsor and IRB. Please contact …
Colon cancer is the third most common cancer worldwide, affecting millions of individuals every year. Currently, the treatment paradigm for resected stage 2 and 3 colon cancer patients typically involves surgery followed by adjuvant chemotherapy to reduce the risk of cancer recurrence. However, the prognosis for these patients varies significantly, with some experiencing a complete …
Merkel cell carcinoma (MCC) is the unsung villain of the skin cancer world – rare, aggressive, and often flying under the radar. MCC is a neuroendocrine skin cancer that usually rears its ugly head as a firm, painless nodule on sun-exposed areas of the skin. Risk factors for this sneaky skin invader include advanced age, …
“How am I doing?”, asked one of my colorectal patients. Ten years ago, I first met John (name changed for privacy), a warm and spirited individual diagnosed with stage 3 colon cancer. After undergoing surgical resection of the primary colon tumor and six months of standard adjuvant chemotherapy with mFOLFOX, John and I optimistically looked …
This post was written by our melanoma/sarcoma nurse navigator Ashlee Jones. She is highly respected by all members of my team to include the nurses, pharmacist, staff, research team, and physicians! I’ve always felt that new patients diagnosed with cancer can initially have a rough start in the journey given the new diagnosis, the array …